Imaging of pharmacologic intervention: Decoding therapeutic mechanism or defining effectiveness?

JACC: Cardiovascular Imaging

Volumn 4, Issue 10, 2011, Pages 1146-1147

  Marwick, Thomas H ^a   Narula, Jagat ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FLUORODEOXYGLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; PIOGLITAZONE; TORCETRAPIB;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; EDITORIAL; GLAUCOMA; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; IMAGING; INTRAOCULAR PRESSURE; MICROVASCULARIZATION; NEOVASCULARIZATION (PATHOLOGY); PLEIOTROPY; PRIORITY JOURNAL; RENAL PROTECTION; THROMBOSIS;

ANTI-INFLAMMATORY AGENTS; AORTIC DISEASES; AORTOGRAPHY; CAROTID ARTERY DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; MALE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 80054090028     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2011.09.003     Document Type: Editorial

References (18)

1. Y.K. Loke, C.S. Kwok, and S. Singh Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies BMJ 342 2011 d1309
2. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471 (Pubitemid 46919772)
3. E. Vucic, S.D. Dickson, and C. Calcagno Pioglitazone modulates vascular inflammation in atherosclerotic rabbits: noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging J Am Coll Cardiol Img 4 2011 1100 1109
4. M. Mizoguchi, N. Tahara, and A. Tahara Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes: a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta imaging J Am Coll Cardiol Img 4 2011 1110 1118
5. S.E. Nissen, S.J. Nicholls, and K. Wolski Comparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial JAMA 299 2008 1561 1573 (Pubitemid 351482795)
6. D.R. Webb, M.J. Davies, and L.J. Gray Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse-wave velocity to infer anti-atherogenic properties of TZDs Diab Obes Metab 12 2010 124 132
7. E. Thorp, G. Kuriakose, Y.M. Shah, F.J. Gonzalez, and I. Tabas Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice Circulation 116 2007 2182 2190 (Pubitemid 350060356)
8. H.C. Gerstein, R.E. Ratner, and C.P. Cannon Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial Circulation 121 2010 1176 1187
9. A.V. Finn, Y. Chandrashekhar, and J. Narula Seeking alternatives to hard end points: is imaging the best APPROACH? Circulation 121 2010 1165 1168
10. Department of Health and Human Services. Food and Drug Administration New drug, antibiotic, and biological drug product regulations: accelerated approval Federal Register 57 1992 13234 13242
11. R.L. Prentice Surrogate endpoints in clinical trials: definition and operational criteria Stat Med 8 1989 431 440 (Pubitemid 19105891)
12. C.M. Pratt, and L.A. Moye The Cardiac Arrhythmia Suppression Trial: background, interim results and implications Am J Cardiol 65 1990 20B 29B (Pubitemid 20031282)
13. P.J. Barter, M. Caulfield, and M. Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122 (Pubitemid 350146106)
14. T.R. Fleming, and D.L. DeMets Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125 1996 605 613 (Pubitemid 126450094)
15. S.J. Nicholls, A. Hsu, and K. Wolski Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome J Am Coll Cardiol 55 2010 2399 2407
16. A. Sugawara, A. Uruno, M. Kudo, K. Matsuda, C.W. Yang, and S. Ito PPARγ agonist beyond glucose lowering effect Korean J Intern Med 26 2011 19 24
17. J. Stephenson Diabetes drug may be associated with increase in risk of bladder cancer JAMA 306 2011 143
18. J.A. Dormandy, B. Charbonnel, and D.J.A. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289 (Pubitemid 41416583)